Literature DB >> 14605290

No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement.

Martin Zeier1, Jolanta Perz, Reinhold P Linke, Ugo Donini, Rüdiger Waldherr, Konrad Andrassy, Anthony D Ho, Hartmut Goldschmidt.   

Abstract

BACKGROUND: High-dose chemotherapy followed by autologous blood stem cell transplantation induces remission of plasma cell dyscrasia in patients with AL amyloidosis. The impact of this treatment on the glomerular amyloid mass is still unknown.
METHODS: In the present study, the quantity of the renal amyloid mass before and more than 3 years after high-dose melphalan treatment and autologous blood stem cell transplantation was assessed in two patients. At the time of the second renal biopsy, both patients were in complete remission without detectable serum and urinary monoclonal IgA-lambda and a normal percentage of plasma cells in the bone marrow.
RESULTS: In both patients with biopsy-proven AL amyloidosis, urinary protein excretion decreased from 7 g/24 h to <2 g/24 h more than 3 years after autologous blood stem cell transplantation. In contrast, glomerular amyloid deposits persisted, as shown in the second biopsy.
CONCLUSION: Despite complete remission of the plasma cell dyscrasia and improvement of glomerular permeability, the amount of glomerular amyloid mass did not regress.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14605290     DOI: 10.1093/ndt/gfg436

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

1.  The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis.

Authors:  Avital Angel-Korman; Aala Jaberi; Vaishali Sanchorawala; Andrea Havasi
Journal:  Amyloid       Date:  2019-10-09       Impact factor: 7.141

Review 2.  [Current diagnostic and therapy of light chain amyloidosis].

Authors:  S O Schönland; T Bochtler; A V Kristen; A D Ho; U Hegenbart
Journal:  Pathologe       Date:  2009-05       Impact factor: 1.011

Review 3.  Transthyretin (TTR) cardiac amyloidosis.

Authors:  Frederick L Ruberg; John L Berk
Journal:  Circulation       Date:  2012-09-04       Impact factor: 29.690

4.  Review of eprodisate for the treatment of renal disease in AA amyloidosis.

Authors:  Adam Rumjon; Thomas Coats; Muhammad M Javaid
Journal:  Int J Nephrol Renovasc Dis       Date:  2012-02-24

5.  Histologic regression of fibrillary glomerulonephritis: the first report of biopsy-proven spontaneous resolution of disease.

Authors:  Miroslav Sekulic; Samih H Nasr; Joseph P Grande; Lynn D Cornell
Journal:  Clin Kidney J       Date:  2017-06-05

Review 6.  Value of repeat renal biopsy in the evaluation of AL amyloidosis patients lacking renal response despite of complete hematologic remission: a case report and literature review.

Authors:  Ping Zhang; Xiuling Chen; Yurong Zou; Wei Wang; Yunlin Feng
Journal:  BMC Nephrol       Date:  2022-03-31       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.